Ligand activation of peroxisome proliferator-activated receptor β/δ (PPARβ/δ) inhibits chemically induced skin tumorigenesis

Carcinogenesis

Volumn 29, Issue 12, 2008, Pages 2406-2414

  Bility, Moses T ^a,b   Devlin Durante, Meghann K ^a,b   Blazanin, Nicholas ^a,b   Glick, Adam B ^a,b   Ward, Jerrold M ^c   Kang, Boo Hyon ^d   Kennett, Mary J ^a   Gonzalez, Frank J ^e   Peters, Jeffrey M ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

^c SOBRAN INC   (United States)

^d Non Clinical Pathology Research Center   (South Korea)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMICAL CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DNA REPLICATION; DNA SYNTHESIS INHIBITION; DRUG MECHANISM; EX VIVO STUDY; FEMALE; IN VIVO STUDY; KERATINOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CANCER; SKIN CARCINOGENESIS; WILD TYPE;

ACETONE; ANIMALS; CARCINOGENS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ENZYME ACTIVATION; FEMALE; KERATINOCYTES; LIGANDS; MICE; MICE, MUTANT STRAINS; PPAR DELTA; PPAR-BETA; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; THIAZOLES;

EID: 57349159202     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn219     Document Type: Article

References (54)

1. Akiyama,T.E. et al. (2005) PPAR ligands: Potential therapies for metabolic syndrome. Curr. Diab. Rep., 5, 45-52.
2. Burdick,A.D. et al. (2006) The role of peroxisome proliferator-activated receptor-β/δ in epithelial cell growth and differentiation. Cell. Signal., 18, 9-20.
3. Desvergne,B. et al. (1999) Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr. Rev., 20, 649-688.
4. Grimaldi,P.A. (2005) Regulatory role of peroxisome proliferator-activated receptor δ (PPARδ) in muscle metabolism. A new target for metabolic syndrome treatment? Biochimie, 87, 5-8.
5. Lee,C.H. et al. (2003) Minireview: Lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 144, 2201-2207.
6. Peraza,M.A. et al. (2006) The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR). Toxicol. Sci., 90, 269-295.
7. Braissant,O. et al. (1996) Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α, -β, and γ in the adult rat. Endocrinology, 137, 354-366.
8. Braissant,O. et al. (1998) Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development. Endocrinology, 139, 2748-2754.
9. Girroir,E.E. et al. (2008) Quantitative expression patterns of peroxisome proliferator-activated receptor=β/δ (PPARβ/δ) protein in mice. Biochem. Biophys. Res. Commun., 371, 456-461.
10. Forman,B.M. et al. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl Acad. Sci. USA 94, 4312-4317.
11. Westergaard,M. et al. (2001) Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. J. Invest. Dermatol., 116, 702-712.
12. Sznaidman,M.L. et al. (2003) Novel selective small molecule agonists for peroxisome proliferator-activated receptor δ (PPARδ)-synthesis and biological activity. Bioorg. Med. Chem. Lett. 13, 1517-1521.
13. Berger,J. et al. (1999) Novel peroxisome proliferator-activated receptor (PPAR) γ and PPARδ ligands produce distinct biological effects. J. Biol. Chem., 274, 6718-6725.
14. Leibowitz,M.D. et al. (2000) Activation of PPARδ alters lipid metabolism in db/db mice. FEBS Lett., 473, 333-336.
15. Oliver,W.R.Jr et al. (2001) A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl Acad. Sci. USA, 98, 5306-5311.
16. Holst,D. et al. (2003) Nutritional regulation and role of peroxisome proliferator-activated receptor δ in fatty acid catabolism in skeletal muscle. Biochim. Biophys. Acta, 1633, 43-50.
17. Luquet,S. et al. (2004) Roles of peroxisome proliferator-activated receptor δ (PPARδ) in the control of fatty acid catabolism. A new target for the treatment of metabolic syndrome. Biochimie, 86 833-837.
18. Tanaka,T. et al. (2003) Activation of peroxisome proliferator-activated receptor delta induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc. Natl Acad Sci. USA, 100, 15924-15929.
19. Wang,Y.X. et al. (2003) Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity. Cell, 113, 159-170.
20. Kitz Kramer,D. et al. (2007) Role of AMP kinase and PPARδ in the regulation of lipid and glucose metabolism in human skeletal muscle. J. Biol. Chem., 282, 19313-19320.
21. Lee,C.H. et al. (2006) PPARδ regulates glucose metabolism and insulin sensitivity. Proc. Natl Acad Sci. USA, 103, 3444-3449.
22. Sprecher,D.L. et al. (2007) Triglyceride: High-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist. Arterioscler. Thromb. Vasc. Biol., 27, 359-365.
23. Kilgore,K.S. et al. (2008) PPARβ/δ ligands as modulators of the inflammatory response. Curr. Opin. Investig. Drugs, 9, 463-469.
24. Peters,J.M. et al. (2008) Role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in gastrointestinal tract function and disease. Clin. Sci., 115, 107-127.
25. Hollingshead,H.E. et al. (2007) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands do not potentiate growth of human cancer cell lines. Carcinogenesis, 28, 2641-2649.
26. Girroir,E.E. et al. (2008) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines. Toxicology, 243, 236-243.
27. Michalik,L. et al. (2001) Impaired skin wound healing in peroxisome proliferator-activated receptor (PPAR)α and PPARβ mutant mice. J. Cell Biol., 154, 799-814.
28. Peters,J.M. et al. (2000) Growth, adipose, brain and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ). Mol. Cell. Biol., 20 5119-5128.
29. Kim,D.J. et al. (2004) Peroxisome proliferator-activated receptor β (δ)-dependent regulation of ubiquitin C expression contributes to attenuation of skin carcinogenesis. J. Biol. Chem., 279, 23719-23727.
30. Kim,D.J. et al. (2006) PPARβ/δ selectively induces differentiation and inhibits cell proliferation. Cell Death Differ. 13, 53-60.
31. Schmuth,M. et al. (2004) Peroxisome proliferator-activated receptor (PPAR)-β/δ stimulates differentiation and lipid accumulation in keratinocytes. J. Invest. Dermatol., 122, 971-983.
32. Tan,N.S. et al. (2001) Critical roles of PPARβ/δ in keratinocyte response to inflammation. Genes Dev., 15, 3263-3277.
33. Strickland,J.E. et al. (1988) Development of murine epidermal cell lines which contain an activated rasHa oncogene and form papillomas in skin grafts on athymic nude mouse hosts. Cancer Res., 48, 165-169.
34. Yuspa,S.H. et al. (1981) Mouse skin cells resistant to terminal differentiation associated with initiation of carcinogenesis. Nature 293, 72-74.
35. Yuspa,S.H. et al. (1980) A survey of transformation markers in differentiating epidermal cell lines in culture. Cancer Res., 40, 4694-4703.
36. Kulesz-Martin,M.F. et al. (1980) Quantitative assay for carcinogen altered differentiation in mouse epidermal cells. Carcinogenesis, 1, 995-1006.
37. Yuspa,S.H. et al. (1986) Cultivation and characterization of cells derived from mouse skin papillomas induced by an initiation-promotion protocol. Carcinogenesis, 7, 949-958.
38. Hough-Monroe,L. et al. (1991) Quantitation of cross-linked protein: An alternative to counting cornified envelopes as an index of keratinocyte differentiation. Anal. Biochem., 199, 25-28.
39. Hennings,H. et al. (1990) Development of an in vitro analogue of initiated mouse epidermis to study tumor promoters and antipromoters. Cancer Res., 50, 4794-4800.
40. Burdick,A.D. et al. (2007) Ligand activation of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits cell growth of human N/TERT-1 keratinocytes. Cell. Signal., 19, 1163-1171.
41. Man,M.Q. et al. (2007) Deficiency of PPARβ/δ in the epidermis results in defective cutaneous permeability barrier homeostasis and increased inflammation. J. Invest. Dermatol., 128, 370-377.
42. Knutsen,G.L. et al. (1986) Gross and microscopic lesions in the female SENCAR mouse skin and lung in tumor initiation and promotion studies. Enviran. Health Perspect., 68, 91-104.
43. Tiano,H.F. et al. (2002) Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res., 62, 3395-3401.
44. Kim,D.J. et al. (2005) Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) inhibits epidermal cell proliferation by down-regulation of kinase activity. J. Biol. Chem., 280, 9519-9527.
45. Lippens,S. et al. (2000) Epidermal differentiation does not involve the pro-apoptotic executioner caspases, but is associated with caspase-14 induction and processing. Cell Death Differ., 7, 1218-1224.
46. Weil,M. et al. (1999) Caspase activation in the terminal differentiation of human epidermal keratinocytes. Curr. Biol., 9, 361-364.
47. Gandarillas,A. et al. (1999) Evidence that apoptosis and terminal differentiation of epidermal keratinocytes are distinct processes. Exp. Dermatol., 8, 71-79.
48. Polakowska,R.R. et al. (1994) Apoptosis in human skin development: morphogenesis, periderm, and stem cells. Dev. Dyn., 199, 176-188.
49. Singh,R.P. et al. (2002) Silymarin inhibits growth and causes regression of established skin tumors in SENCAR mice via modulation of mitogen-activated protein kinases and induction of apoptosis. Carcinogenesis, 23, 499-510.
50. Ghosh,M. et al. (2007) COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARδ activation. J. Exp. Med., 204, 2053-2061.
51. Fernandez,P.M. et al. (2004) Tissue factor and fibrin in tumor angiogenesis. Semin. Thromb. Hemost., 30, 31-44.
52. Mousa,S.A. (2005) Anti-thrombotics in thrombosis and cancer. Future Oncol., 1, 395-403.
53. Mousa,S.A. (2005) Antithrombotics in thrombosis and cancer. Hamostaseologie, 25, 380-386.
54. Rickles,F.R. (2006) Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb., 35, 103-110.